RxDoctor Payments Data

Jill Wettstein, APRN

Acute Care · Wichita, KSNPI 1437773025

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abiomed at 24.7% of the total. Reporting peaked in 2024 at $807 and has fallen 59.4% since, to $327 in 2025.

$1,837in general payments, 2019–2025

Across 38 payments — averaging $48.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$454
  • Edwards Lifesciences$361
  • Medtronic$267
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$244
  • Novo Nordisk$167
  • Recor Medical Inc$110
  • plus $233 from 8 others

What the payments were for

  • Food & beverage$1,837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,837 in reported general payments places this provider in the 80th percentile of 113 acute care providers in Kansas.

See all acute care providers in Kansas

Medicare billing

Part B allowed, 2024
$15,092
Medicare patients
152
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$49,436
XareltoRivaroxaban19$14,462
BrilintaTicagrelor26$13,789
EntrestoSacubitril/Valsartan13$8,445
FarxigaDapagliflozin Propanediol11$5,995
ClopidogrelClopidogrel Bisulfate362$2,325
Bumetanide60$1,834
Pantoprazole Sodium98$752
Digoxin14$510
Metoprolol Tartrate133$432
Atorvastatin Calcium56$366
Metoprolol Succinate60$341
Potassium Chloride29$307
Furosemide91$258
Isosorbide Mononitrate ErIsosorbide Mononitrate20$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$15$14,46219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 113 acute care providers in Kansas.

Other acute care in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →